Perspective Therapeutics, Inc. · AMEX:CATX
Perspective Therapeutics — Investor Presentation (June 2026)
56 slides from Perspective Therapeutics's investor presentation, Jun 1, 2026
Slide 1: Redefining Oncology Treatment with Next-Generation Radiopharmaceuticals
Redefining Oncology Treatment with Next-Generation Radiopharmaceuticals
Slide 2: Legal Disclaimers
Legal Disclaimers This presentation contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Statements in this presentation that are not statements of historical fact are forward-looking statements. Words such as “may,” “will,” “s
Slide 3: Engineering the Alpha Advantage in Targeted Oncology
Engineering the Alpha Advantage in Targeted Oncology
Slide 4: Unlocking New Treatment Options Across Solid Tumors
Unlocking New Treatment Options Across Solid Tumors:
Slide 5: Optimizing the Entire System
Optimizing the Entire System
Slide 6: Rapidly Advancing Best-in-Class Next Generation Radiopharmaceuticals
Rapidly Advancing Best-in-Class Next Generation Radiopharmaceuticals
Slide 7: Optimizing Structural Chemistry
Optimizing Structural Chemistry:
Slide 8: Choosing The Right Isotope
Choosing The Right Isotope Lead (?12Pb) advantages over beta and other alpha emitters 212Db Advantage Better anti-tumor activity > Better safety profile > Cleaner decay chain > Better clinical profile Isotope access & scalability > Better patient management > Better patient selection “Daughter isoto
Slide 9: Not All 212Pb Programs Are Created Equal
Not All ²¹²Pb Programs Are Created Equal
Slide 10: * Phage display followed by
| _ i : | [ 1 of 1 * Phage display followed by affinity maturation * Bioconjugate chemistry and further optimization * In vitro and in vivo binding assays identified lead candidates? » | 8 i PERSPECTIVE HE TICS
Slide 11: Advancing a Theranostic Approach
Advancing a Theranostic Approach:
Slide 12: Solid Tumors are an Attractive Market for Radiopharmaceuticals
Solid Tumors are an Attractive Market for Radiopharmaceuticals
Slide 13: Expanding the Addressable Market
Expanding the Addressable Market
Slide 14: Direct-to-Hospital Delivery through Integrated Isotope Production
Direct-to-Hospital Delivery through Integrated Isotope Production
Slide 15: Daily Production at Regional Sites Ensures Supply of Ready-to-Administer Product
Daily Production at Regional Sites Ensures Supply of Ready-to-Administer Product
Slide 16: Reaching the Largest Addressable Market with Regional Manufacturing
Reaching the Largest Addressable Market with Regional Manufacturing
Slide 17: Advancing a Diverse Wholly Owned 212Pb-Based Oncology Portfolio
Advancing a Diverse Wholly Owned 212Pb-Based Oncology Portfolio
Slide 18: SSTR2+ Neuroendocrine Tumors is a Large, Growing Market with Significant Unmet Need
SSTR2+ Neuroendocrine Tumors is a Large, Growing Market with Significant Unmet Need
Slide 19: VMT-α-NET: Potential First-in-Class 212Pb-Radioligand Therapy Targeting SSTR2
VMT-⍺-NET: Potential First-in-Class 212Pb-Radioligand Therapy Targeting SSTR2
Slide 20: Ongoing Phase 1/2a to Establish Broad Therapeutic Window For VMT-α-NET in NETs
Ongoing Phase 1/2a to Establish Broad Therapeutic Window For VMT-⍺-NET in NETs
Slide 21: VMT-α-NET: Baseline Patient Characteristics in ASCO 2026 Data Analysis
VMT-⍺-NET: Baseline Patient Characteristics in ASCO 2026 Data Analysis
Slide 22: Patient Exposure and Follow-up with [212Pb]VMT-α-NET in ASCO 2026 Data Analysis
Patient Exposure and Follow-up with [212Pb]VMT-α-NET in ASCO 2026 Data Analysis
Slide 23: VMT-α-NET Responses Deepen Over Time
VMT-α-NET Responses Deepen Over Time
Slide 24: VMT-α-NET: Durable Disease Control Across All Doses
VMT-⍺-NET: Durable Disease Control Across All Doses
Slide 25: Spider Plot of Tumor Change Over Time by Patient
Spider Plot of Tumor Change Over Time by Patient
Slide 26: Best-in-class Safety Profile
Best-in-class Safety Profile1
Slide 27: Blood Creatinine During Follow-up for All Patients Treated (n=68)
Blood Creatinine During Follow-up for All Patients Treated (n=68)
Slide 28: VMT-α-NET's Compelling Profile Supports Potential Registration Study at Current Dose Level
VMT-α-NET’s Compelling Profile Supports Potential Registration Study at Current Dose Level
Slide 29: Checkpoint Inhibitors Transformed Care of Melanoma but Leave Many Patients Behind
Checkpoint Inhibitors Transformed Care of Melanoma but Leave Many Patients Behind
Slide 30: VMT01: Potential First-in-Class 212Pb Therapy Targeting MC1R for Melanoma
VMT01: Potential First-in-Class 212Pb Therapy Targeting MC1R for Melanoma
Slide 31: Ongoing Phase 1/2a Open-Label Trial For VMT01 in Melanoma
Ongoing Phase 1/2a Open-Label Trial For VMT01 in Melanoma
Slide 32: Preliminary Anti-tumor Activity Observed at 3.0 mCi Dose of VMT01
Preliminary Anti-tumor Activity Observed at 3.0 mCi Dose of VMT01
Slide 33: Treatment Emergent Adverse Events (All Grades, Occurring in ≥ 10% of Patients)
Treatment Emergent Adverse Events (All Grades, Occurring in ≥ 10% of Patients)
Slide 34: VMT01 is Well-tolerated with Initial Anti-tumor Activity Supporting Further Development
VMT01 is Well-tolerated with Initial Anti-tumor Activity Supporting Further Development
Slide 35: FAP-α is an Attractive Cancer Target with Broad Solid Tumor Potential
FAP-ɑ is an Attractive Cancer Target with Broad Solid Tumor Potential
Slide 36: PSV359: Potential First-in-Class 212Pb Therapy Targeting FAP-α for Solid Tumors
PSV359: Potential First-in-Class 212Pb Therapy Targeting FAP-ɑ for Solid Tumors
Slide 37: Ongoing Open-label Phase 1/2a Trial For PSV359 in Advanced Solid Tumors
Ongoing Open-label Phase 1/2a Trial For PSV359 in Advanced Solid Tumors
Slide 38: PSV359 has Improved Tumor Retention, Highlighting its Potential as a Therapeutic Agent
PSV359 has Improved Tumor Retention, Highlighting its Potential as a Therapeutic Agent
Slide 39: Strong IP Portfolio Covering All Aspects of Radiopharmaceutical Value Chain
Strong IP Portfolio Covering All Aspects of Radiopharmaceutical Value Chain
Slide 40: Strong Financial Position
Strong Financial Position Funding into late 2027 Cash, cash equivalents and short-term investments as of March 31, 2026 ~$271 million Share count as of March 31, 2026 ~114.0 million Outstanding common stock warrants & options as of March 31, 2026 ~20.5 million Based on our current plans, we believe
Slide 41: A Decade of Deliberate, End-to-End Engineering
A Decade of Deliberate, End-to-End Engineering
Slide 42: Built Over a Decade: The Only Fully Integrated Radiopharmaceutical Platform from Isotope to Patient
Built Over a Decade: The Only Fully Integrated Radiopharmaceutical Platform from Isotope to Patient 42 *As of May 7, 2026. Category defining radiopharmaceuticals Clinical proof-of-concept established 108 issued, allowed and pending patents* Regional network for direct to hospital delivery Proprietar
Slide 43: Slide 43
Slide 44: Abbreviations
Abbreviations AACR: American Association for Cancer Research AE: adverse event ALP: alkaline phosphatase ALT: alanine transaminase ASCO: American Society of Clinical Oncology ASCO-GI: ASCO Gastrointestinal Cancers Symposium AST: aspartate aminotransferase AUC: area under the curve CR: complete respo
Slide 45: APPENDIX
APPENDIX
Slide 46: Deeply Experienced Management Team in Radiopharmaceuticals and Drug Development
Deeply Experienced Management Team in Radiopharmaceuticals and Drug Development 20+ years of exper ein biotechnology companies; public and private companies; ‘oncology and nuclear pharmacy Thijs Spoor Chief Executive Officer - cotynia Srsiswio TEE verify.» Vewront ror Aa om BD An accomplished financ
Slide 47: NETs Trials
NETs Trials Study NETTER-12 Randomized 2:1 (+/-octreotide) N=229 Status Supported registration Dose Level 4x QBW | 200 mCi (administered) Patient Population Prior PRRT Median time from dx ORR AEs (>20%) Grade 3+ (>10%) (CR/PR) 277Lu-DOTATATE 177Lu-DOTATATE 377Lu-EDOTREOTIDE® 212pb-DOTAMTATE® 225\c-D
Slide 48: Patient with Confirmed PR After [212Pb]VMT-α-NET Treatment
Patient with Confirmed PR After [212Pb]VMT-α-NET Treatment
Slide 49: Refractory Metastatic Melanoma Trials
Refractory Metastatic Melanoma Trials
Slide 50: ICI Combo Rationale: Strong Synergy with [212Pb]VMT01 in Melanoma
ICI Combo Rationale: Strong Synergy with [212Pb]VMT01 in Melanoma
Slide 51: Strong intellectual property portfolio
Strong intellectual property portfolio Perspective-owned/Exclusively-licensed IP 19 Issued Patents (full patent term expires 2036-2044, with potential PTE) * Composition of matter for radiopharmaceutical compounds targeting SSTR2, FAP-a, and MC1R * System and methods for generating Pb-212 radionucli
Slide 52: 212Pb Isotope Decay Chain and Importance of the Pb-specific Chelator
212Pb Isotope Decay Chain and Importance of the Pb-specific Chelator Thorium Where the drug goes = where the 1sy alpha particle is deposited @) OH 2 Bj Bismuth 61m * Perspective’s proprietary chelator retains ~95% of 2128] after transition in drug formulation? * Generic chelators leak the 2?2Bi alph
Slide 53: Construct designed for better clinical outcome
Construct designed for better clinical outcome
Slide 54: 212Pb Uniquely Suited for Combination with Immune Check Point Inhibitors
212Pb Uniquely Suited for Combination with Immune Check Point Inhibitors
Slide 55: 225Ac Isotope Decay Chain and Potential for Off-target Toxicity
225\c Isotope Decay Chain and Potential for Off-target Toxicity Isotope Supply Production Therapy Bismuth 46m | A¥P1KO] 32310 1-440 404 [eHUDIOg Alpha-particle emission OH imparts sufficient “recoil” fe) energy to break chemical aN s~¢ bonds N O o = Target Organs @ Liver @) Kidneys @) ‘ay PERSPECTIV
Slide 56: Isotope Decay Chain — Product Implications
Isotope: Decay Chain — Product Implications Post final radiolabeling and purification, alpha and beta emitting daughters of 2°Ac build up fast 225A) cay ghter Ingrowt! Dose Vial Unbound Isotopes m25Ac m221Fr mw 217At mi 2238) me 205T] m213Po 4x more unlabeled daughter activity in about 4 hrs l | 8 R
Perspective Therapeutics — Investor Presentation (June 2026) on 6ix